LB Pharmaceuticals Inc Common Stock
LBRXHealthcare|Biotechnology|US
$42.01
+3.92 (+10.29%)
DCF Value
$9.67
Tangible Book / Share
$12.63
Cash / Share
$12.21
Financials
Financial Snapshot
Market Cap
$1.36B
Enterprise Value
$956.6M
Revenue (TTM)
$0.00
Net Income (TTM)
-$141.2M
Cash & Investments
$403.8M
Net Cash
$398.6M
Free Cash Flow (TTM)
-$143.8M
Operating CF (TTM)
-$143.3M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$403.8M
Quarterly Burn
$35.8M
Monthly Burn
$11.9M
Est. Runway
~11.3 quarters
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Investments | $21.4M | $43.3M | $28.0M | $295.2M | $403.8M | |
| Operating Cash Flow | -$2.7M | -$12.1M | -$53.1M | -$35.2M | -$143.3M | |
| Free Cash Flow | -$2.7M | -$12.1M | -$53.8M | -$35.3M | -$143.8M | |
| Capital Expenditure | $0.00 | -$25.0K | -$769.0K | -$52.0K | -$505.0K | |
| Financing Cash Flow | $23.0M | $33.7M | $38.3M | $302.6M | $233.6M |
R&D Spending
R&D (TTM)
$118.8M
R&D Intensity
—
R&D Growth vs Prior
+609.4%
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $1.3M | $7.8M | $51.2M | $16.7M | $118.8M | |
| SG&A | $1.5M | $3.5M | $13.7M | $13.7M | $33.4M |
Income Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $179.0K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | -$179.0K | |
| R&D | $1.3M | $7.8M | $51.2M | $16.7M | $118.8M | |
| SG&A | $1.5M | $3.5M | $13.7M | $13.7M | $33.4M | |
| Operating Income | -$2.8M | -$11.4M | -$64.8M | -$30.4M | -$86.5M | |
| Interest Expense | $2.2M | $4.8M | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$14.3M | -$6.3M | -$63.1M | -$25.2M | -$141.2M | |
| Net Income | -$14.3M | -$6.3M | -$63.1M | -$25.2M | -$141.2M | |
| EPS (Diluted) | -4.05 | -1.77 | -17.83 | -1.00 | -4.62 | |
| EBITDA | -$12.2M | -$1.4M | -$63.0M | -$24.9M | -$80.7M | |
| Shares Out. (M) | 3.54 | 3.54 | 3.54 | 25.30 | 33.08 |
Balance Sheet
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $21.4M | $15.0M | $23.0M | $250.2M | $403.8M | |
| Short-Term Investments | $0.00 | $28.3M | $5.0M | $45.0M | $0.00 | |
| Total Current Assets | $21.5M | $45.6M | $28.9M | $308.4M | $447.1M | |
| Total Assets | $21.5M | $45.7M | $33.5M | $312.9M | $453.4M | |
| Total Current Liabilities | $469.0K | $2.6M | $8.1M | $7.4M | $30.3M | |
| Long-Term Debt | $24.1M | $0.00 | $0.00 | $0.00 | $4.2M | |
| Total Liabilities | $50.3M | $80.1M | $128.1M | $11.6M | $35.7M | |
| Stockholders' Equity | -$28.8M | -$34.5M | -$94.6M | $301.3M | $417.6M | |
| Retained Earnings | -$34.9M | -$41.2M | -$104.3M | -$129.5M | -$259.3M |
Cash Flow Statement
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.7M | -$12.1M | -$53.1M | -$35.2M | -$143.3M | |
| Capital Expenditure | $0.00 | -$25.0K | -$769.0K | -$52.0K | -$505.0K | |
| Free Cash Flow | -$2.7M | -$12.1M | -$53.8M | -$35.3M | -$143.8M | |
| Investing Cash Flow | $123.0K | -$28.0M | $23.2M | -$39.9M | -$144.6M | |
| Financing Cash Flow | $23.0M | $33.7M | $38.3M | $302.6M | $233.6M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $302.6M | $248.8M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $25.0M | $725.0K | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $431.0K | $295.0K | $3.2M | $0.00 | $11.1M | |
| Net Change in Cash | $20.4M | -$6.4M | $8.5M | $227.2M | -$54.7M |
Dilution Tracker
Shares outstanding grew 614.5% over 5 years — significant dilution
Shares Outstanding
32M
5-Year Share Growth
+614.5%
Stock Issuance (TTM)
$248.8M
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Shares Out. (M) | 3.54 | 3.54 | 3.54 | 25.30 | 33.08 | |
| Change vs Prior % | — | 0.0% | -0.0% | 614.8% | 30.8% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $302.6M | $248.8M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $431.0K | $295.0K | $3.2M | $0.00 | $11.1M |
Margins & Profitability
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| ROE % | 49.8% | 18.2% | 66.7% | -8.4% | -39.5% | |
| ROA % | -66.8% | -13.7% | -188.2% | -8.1% | -31.1% | |
| ROIC % | -13.4% | -26.4% | -250.2% | -9.9% | -20.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -305.0% | -469.9% | 53.1% | |
| Net Income | 0.0% | 56.3% | -905.6% | 60.1% | |
| EPS (Diluted) | 0.0% | 56.3% | -907.3% | 94.4% | |
| Operating Cash Flow | 0.0% | -343.3% | -338.7% | 33.6% | |
| Free Cash Flow | 0.0% | -344.2% | -344.1% | 34.5% | |
| R&D Expense | 0.0% | 482.8% | 552.3% | -67.3% | |
| SG&A Expense | 0.0% | 141.4% | 286.8% | 0.0% | |
| Total Assets | 0.0% | 112.4% | -26.6% | 833.2% | |
| Book Value / Share | 0.0% | -19.6% | -174.4% | 144.6% | |
| Debt | 0.0% | -100.0% | 0.0% | -3.6% | |
| Diluted Shares | 0.0% | 0.0% | -0.0% | 614.8% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B3.33
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$9.67
Tangible Book / Share
$12.63
Net Current Assets / Share
$12.75
Graham Net-Net
$11.13
Cash / Share
$12.21
| Metric | Trend | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| P/E Ratio | -4.27 | -9.77 | -0.97 | -22.26 | -9.09 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -2.13 | -1.78 | -0.65 | 1.87 | 3.33 | |
| EV/EBITDA | -5.25 | -32.02 | -0.67 | -12.72 | -11.85 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
22.47
Safe
Piotroski F-Score
0
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $4.9M |
| Net Income | -$144.0M | -$126.4M | -$141.9M |
| EPS | $-5.65 | $-5.32 | $-5.51 |
| # Analysts (EPS) | 5 | 8 | 6 |